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doi:10.1016/S1078-5884(08)00093-2, available online at http://www.sciencedirect.com onSelected Abstracts from the April Issue of the Journal of Vascular Surgery*Open repair of juxtarenal aortic aneurysms (JAA) remains a safe option
in the era of fenestrated endografts
A.W. Knott, M. Kalra, A.A. Duncan, N.R. Reed, T.C. Bower, T.L. Hoskin,
G.S. Oderich and P. Gloviczki
Objectives. Widespread application of infrarenal endovascular aneurysm re-
pair (EVAR) has resulted in a proportionate increase in open juxtarenal aortic
aneurysm (JAA) repairs. Fenestrated endograft technology for JAA is devel-
oping rapidly, but only limited outcomes are known. The aim of this study
was to review our open JAA experience in an era of fenestrated endograft
technology, identify factors associated with increased surgical risk, determine
early and midterm outcome, and provide a basis for comparison for future
endovascular procedures.
Methods. Data from 126 consecutive patients who underwent elective JAA re-
pair requiring suprarenal aortic clamping from 2001 to 2006 were analyzed
retrospectively. Electronic medical chart reviews were used to record 30-
day complication rates. Multivariate analyses were performed to identify
risk factors associated with surgical morbidity. Mail-out questionnaires and
telephone surveys were conducted to determine long-term follow-up.
Results. Ninety-eight males and 28 females (median age 74 years; range 55 to
93) were included in the study. Preoperative risk factors included: coronary
artery disease (CAD) 58%, pulmonary disease 41%, renal insufficiency (serum
creatinine [Cr] > 1.5mg/dL) 17%, and diabetes 9%. Fifteen patients under-
went concomitant renal artery revascularization. Mean operative time was
319 minutes (range 91 to 648). Thirty-day mortality was 1/126 (0.8%). Median
hospital length of stay was 7 days (range 3 to 85); median intensive care unit
length of stay was 2 days (1 to 64). Complications included renal insufficiency
(Cr increase > 0.5 mg/dL) in 22 (18%), cardiac in 17 (13%), and pulmonary in
14 (11%). Five patients required temporary hemodialysis; only one after hos-
pital dismissal. Mean follow-up was 48 months (range 9-80). On multivariate
analysis, age  78 years (P = .001), male gender (P = .04), hypertension (P
=.01), previous myocardial infarction (P = .047), and diabetes (P =.009)
were predictive of cardiac complications. Renal artery revascularization (P
= .01) and prior MI (P = .04) were multivariate predictors of pulmonary com-
plications. Both prolonged operative (351 minutes, P = .02) and renal ische-
mia (23 minutes, P =.004) times predicted postoperative renal insufficiency.
One, 3, and 5-year cumulative survival rates were 93.9%, 78.3%, and 63.8%,
respectively and were not significantly different than an age- and gender-
matched sample of the US population (P = .16). Mortality was not predicted
by any specific risk factors.
Conclusions. Open surgical repair of JAA is associated with low mortality
and remains the gold standard. Although 18% had renal complications,
only one patient had permanent renal failure. Patients with a combination
of physiologic and anatomic risk factors identified on multivariate analysis
may benefit from fenestrated endograft repair.Device-specific aneurysm sac morphology after endovascular aneurysm
repair: Evaluation of contemporary graft materials
H.S. Broker, K.I. Foteh, E.H. Murphy, C.M. Davis, G.P. Clagett, J.G. Modrall,
C.J. Buckley and F.R. Arko
Objective. This study analyzed device-specific aneurysm sac morphology af-
ter endovascular aneurysm repair (EVAR) with low-permeability devices.
Methods. Between September 2004 and May 2006, 122 patients were treated
with EVAR. Three different devices were implanted: 47 Zenith (Cook, Indian-
apolis, Ind), 46 AneuRx (Medtronic, Santa Rosa, Calif) with Resilient Dacron
Graft Material, and 29 Excluder (W. L. Gore & Associates, Flagstaff, Ariz)
with low-porosity polytetrafluoroethylene (PTFE). Patients were followed
up at 1, 6, and 12 months and then biannually with computed tomography
(CT) angiography. Standard axial two-dimensional CT measurements were
obtained and compared with preoperative imaging. The preoperative scan
served as a baseline, and the minor axis diameter, measured at the largestYEJVS3122_3070_proof  27
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measurement at follow-up.
Results. Patient age, sex, and preoperative aneurysm morphology were sim-
ilar among groups. Patients receiving the Zenith endograft had a significantly
larger neck diameter; however, there was no difference in the neck length be-
tween groups. The rate of type II endoleaks was similar for the Zenith (17%),
AneuRx (17%), and Excluder (14%). At 1, 6, 12, and 18 months, all three grafts
were associated with sac shrinkage. The resulting decreases in mean aneu-
rysm size at 18 months and corresponding shrinkage were Zenith, 11%, 6.4
 1.8 mm; AneuRx, 18.9%, 2.7  2.7 mm; and the Excluder, 5.5%, 3.3  0.9
(P < .05). The sac size in the 19 patients with a type II endoleak decreased
8.06% compared with a 15.43% decrease in sac size in patients without endo-
leak at 6 months. No significant sac expansion 5 mm has been observed
among any of the groups to date.
Conclusions. Sac regression with all devices appears to have been favorably
influenced by the new generation of graft materials and is improved com-
pared with published reports of older generation graft materials for the
AneuRx and Excluder. However, there is a trend toward greater sac regres-
sion with devices using Dacron vs PTFE. The relationship of aneurysm mor-
phology and long-term effects on aortic stent grafts is yet to be determined.A prospective evaluation of C-reactive protein in the progression of
carotid artery stenosis
Z.M. Arthurs, C. Andersen, B.W. Starnes, V.Y. Sohn, P.S. Mullenix and
J. Perry
Objective. Our institution previously reported an association between ele-
vated C-reactive protein (CRP) and carotid artery stenosis. Based on this find-
ing, we sought to further evaluate the association of CRP levels with
ultrasound progression of carotid artery stenosis, and/or clinical events.
Methods. A prospective observational study of patients evaluated for carotid
artery stenosis was performed at a tertiary medical center from 2003-2007.
Patients underwent serial lab draws for serum CRP, as well as serial duplex
ultrasounds of their carotid bifurcations. Examinations were performed at
6-month intervals. Initial risk factors and CRP levels were evaluated with
univariate statistics. Ultrasound progression of disease was evaluated with
Kaplan-Meier curves and Cox regression analysis.
Results. During the study period, 271 patients completed study requirements
with a mean follow-up of 37 (6) months. Initial duplex examination re-
vealed 114 (41%) of patients had 0% to 15%, 94 (35%) had 16% to 49%, and
63 (23%) had 50% to 79% stenosis of the carotid bifurcation. Sixty-three pa-
tients (23%) demonstrated progression of disease by ultrasound examination,
27 (10%) progressed to carotid endarterectomy, and three (1%) experienced
a stroke during follow-up. Mean CRP levels were higher among patients
that progressed on duplex examination (6.7  1.28 vs 4.6  0.4 mg/dl, P <
.05). Kaplan-Meier analysis revealed a significant difference in freedom
from progression of carotid artery disease for patients with 1st and 3rd quar-
tile CRP levels (log-rank test P < .05). Adjusting for diabetes, hyperlipidemia,
hypertension, coronary artery disease, aspirin or other anti-inflammatory
uses, and statin therapy, 4th quartile CRP was independently associated
with disease progression (OR 1.8, 95% CI; 1.03-2.99, P < .05).
Conclusions. High CRP levels predict ultrasound progression of disease in
patients with carotid artery stenosis. In addition, CRP levels may provide
additional information to help guide ultimate therapy for evaluation and
follow-up of patients with borderline lesions identified by duplex exam.A simple subclassification of American Society of Anesthesiology III
patients undergoing peripheral revascularization based on functional
capacity
H.H. Dosluoglu, J. Wang, L. DeFranks-Anain, M. Rainstein and N.D. Nader
Purpose. The American Society of Anesthesiology (ASA) classification re-
mains the most widely used risk-stratification system in the world. However,February 2008  501/503
f European Society for Vascular Surgery.
502 Abstractsit is not practical in patients undergoing revascularization procedures be-
cause most are classified as ASA III. We hypothesized that ASA III patients
can be subdivided into two subgroups, ASA IIIA and ASA IIIB, simply based
on their preoperative functional capacity measured in metabolic equivalents
(METS) of <4 or 4, which would allow the largest group of vascular surgery
patients to be appropriately subgrouped for their predicted early and late
postoperative morbidity and mortality.
Methods. All charts of 482 patients (99% men) who underwent revasculariza-
tion for disabling claudication or critical limb ischemia between June 2001
and October 2006 were reviewed for demographics, comorbidities, operative
and interventional details, postoperative complications, and outcomes defined
as myocardial infarction, stroke, and death. Preoperative functional capacity
information was obtained from the anesthesia records in the electronic charts.
Results. There were 35 patients (7%) in ASA II, 371 patients (77%) in ASA III
(45% in ASA IIIA, 32% in ASA IIIB) and 76 patients (16%) in ASA IV. The
age, albumin level, prevalence of coronary artery disease, diabetesmellitus, ce-
rebrovasculardisease, renal insufficiency (creatinine>1.5mg/dL), critical limb
ischemia, and length of stay were significantly higher in ASA IIIB than IIIA pa-
tients. Significantly more myocardial infarctions and deaths occurred in IIIB
than in IIIA patients. The overall survival rate was significantly better in ASA
IIIA than in ASA IIIB patients. A univariate Cox proportional model identified
coronary artery disease, diabetes mellitus, chronic obstructive pulmonary dis-
ease (COPD), renal insufficiency, hypercholesterolemia, presence of critical
limb ischemia, and preoperative albumin level of<3 g/dL or3 g/dL as being
significantly associatedwith survival.Multivariate analysis showedbeingASA
IIIA or IIIB is an independent predictor of survival, after adjusting for age, cor-
onary artery disease, hyperlipidemia, COPD, and preoperative albumin levels.
Conclusion. Functional capacity assessment is an integral part of routine pre-
operative anesthesia evaluation, and we found this to be very reliable in pre-
dicting postoperative morbidity and mortality as well as overall survival in
ASA III patients undergoing peripheral revascularization. This simple mod-
ification allows ASA III patients (approximately 80% of vascular patients) to
be unbundled into two very distinct subgroups, which will potentially lead to
a more accurate preoperative risk assessment.The efficacy and safety of closure of brachial access using the
AngioSeal closure device: Experience with 161 interventions in
diabetic patients with critical limb ischemia
T. Lupattelli, J. Clerissi, G. Clerici, D.P.Minnella, A.Casini, S. Losa andE. Faglia
Purpose. This study retrospectively evaluated the efficacy and safety of the 6F
Angio-Seal (St. Jude Medical, St. Paul, Minn) as a closure device for transbra-
chial artery access for endovascular procedures in diabetic patients with crit-
ical limb ischemia.
Methods. From January 2005 and September 2007, 1887 diabetic patients un-
derwent interventional procedures in the lower limbs at a two diabetic foot
centers. Patients presented with rest pain (16%), ulcers (80%), or gangrene
(4%). Systemic anticoagulation with sodium heparin (70 IU/kg) was obtained
for all patients at the beginning of the endovascular treatment. A total of 249
brachial arteries (238 patients) were evaluated for possible Angio-Seal use af-
ter endovascular recanalization of the leg. Color Doppler ultrasound imaging
of the artery was obtained before revascularization only in patients with pre-
vious Angio-Seal placement in the brachial artery. No further imaging studies
were done in the remaining brachial arteries where the Angio-Seal was de-
ployed at the operator’s discretion. Impairment or disappearance of the ra-
dial pulse or onsets of hand ischemia or hand pain, or impairment of hand
function during or at the end of the endovascular revascularization were
all regarded as contraindications to Angio-Seal usage. Evidence of a highly
calcified plaque of the brachial artery access site at the time of vessel puncture
was regarded as an absolute contraindication to the Angio-Seal use. Patients
were seen before discharge, at 1, 3, and 8 weeks after the procedure, and at 3-
month intervals thereafter. Complications included hemorrhage, pseudoa-
neurysm, infection, and vessel occlusion.
Results. A total of 1947 Angio-Seal collagen plugs were deployed in 1709 di-
abetic patients (90.5%). The Angio-Seal was used for brachial artery closure in
159 patients (8.4%) in 161 procedures (159 in the left, 2 in the right brachial
artery). In 79 patients (4.2%) in 88 procedures (87 in the left and 1 in the right
brachial artery), the device was deemed contraindicated due to small vessel
size in 73 patients (92.4%) or presence of calcium at the access site in fiveEur J Vasc Endovasc Surg Vol 35, April 2008patients (6.3%). One patient (1.3%) refused the collagen plug closure after re-
vascularization. The non-Angio-Seal group was evaluated for comparison.
The success rate for achieving hemostasis in the Angio-Seal group was
96.9%. Five major complications (3.1%) at 30 days consisted of two puncture
site hematomas >4 cm, two brachial artery occlusions, and one brachial ar-
tery pseudoaneurysm, with three patients requiring open surgery. Minor
complications (7.50%) were three puncture site hematomas < 4 cm, three ooz-
ing of blood from the access site, and six patients had mild pain in the cubital
fossa. No further complications were recorded in the 14-month follow-up
(range 1e25 months) of a total of 140 patients.
Conclusions. This retrospective study shows that the 6F Angio-Seal is a valu-
able and safe vascular closure device for transbrachial access in diabetic pa-
tients undergoing interventional procedures for critical limb ischemia.Predictors of lower extremity arterial injury after total knee or total hip
arthroplasty
C.J. Abularrage, J.M. Weiswasser, K.J. DeZee, M.B. Slidell, W.G. Henderson
and A.N. Sidawy
Objective. Lower extremity arterial injury is a rare complication following to-
tal knee (TKA) or total hip arthroplasty (THA). To date, no multi-institutional
study has identified preoperative factors that may portend increased risk for
these injuries. We queried a large clinical database for the incidence and pre-
dictors of arterial injury and/or compromise following lower extremity
arthroplasty.
Methods. Prospectively collected preoperative and postoperative data by the
National Surgical Quality Improvement Program (NSQIP) of the Veterans Af-
fairs Medical Centers were analyzed. All patients from 1995 to 2003 in the
NSQIP database who underwent TKA or THAwere identified via CPTcodes.
NSQIP defined, 30-day, postoperative outcomes were analyzed. Data were
compared using bivariable analysis, as well as limited multivariable logistic
regression.
Results. A total of 41,633 arthroplasties (24,029 TKA, 2077 redo-TKA, 13,494
THA, 2033 redo-THA) were identified in the NSQIP database. A total of 34
(0.08%) lower extremity arterial injuries were recognized (0.08% TKA,
0.19% redo-TKA, 0.04% THA, 0.20% redo-THA). Eighteen injuries were re-
paired on the same day of surgery (seven intraop, 11 postop), eight between
postoperative days 1 and 5, and 8 between days 6 and 30. Only two patients
underwent lower extremity amputation (overall limb loss rate of 5.9% of pa-
tients who had arterial injury). Statistically significant predictors of lower ex-
tremity arterial injury identified on logistic regression analysis included redo
procedure (odds ratio [OR] 2.7, 95% confidence interval [CI] 1.2-6.0, P = .013)
and African American race (OR 2.5, 95% CI 1.2-5.3, P = .02).
Conclusion. Lower extremity arterial injury was exceedingly rare after total
knee or total hip arthroplasty. There is an increased incidence in African
American patients and those undergoing redo arthroplasty. Among patients
who sustain vascular injury, excellent limb salvage rates can be achieved with
close postoperative surveillance to achieve early detection and repair of
injuries.Comprehensive surgical management of the competitive athlete with
effort thrombosis of the subclavian vein (Paget-Schroetter syndrome)
S.J. Melby, S. Vedantham, V.R. Narra, G.A. Paletta Jr, L. Khoo-Summers,
M. Driskill and R.W. Thompson
Objectives. The results of treatment for subclavian vein effort thrombosis
were assessed in a series of competitive athletes.
Methods. A retrospective review was conducted of high-performance athletes
who underwent multidisciplinary management for venous thoracic outlet
syndrome in a specialized referral center. The overall time required to return
to athletic activity was assessed with respect to the timing and methods of
diagnosis, initial treatment, operative management, and postoperative care.
Results. Between January 1997 and January 2007, 32 competitive athletes (29
male and 3 female) were treated for venous thoracic outlet syndrome, of
which 31% were in high school, 47% were in college, and 22% were profes-
sional. The median age was 20.3 years (range, 16-26 years). Venous duplex ul-
trasound examination in 21 patients had a diagnostic sensitivity of 71%, and
503Abstractsthe mean interval between symptoms and definitive venographic diagnosis
was 20.2  5.6 days (range, 1e120 days). Catheter-directed subclavian vein
thrombolysis was performed in 26 (81%), with balloon angioplasty in 12
and stent placement in one. Paraclavicular thoracic outlet decompression
was performed with circumferential external venolysis alone (56%) or direct
axillary-subclavian vein reconstruction (44%), using saphenous vein panel
graft bypass (n = 8), reversed saphenous vein graft bypass (n = 3), and saphe-
nous vein patch angioplasty (n = 3). In 19 patients (59%), simultaneous crea-
tion of a temporary (12 weeks) adjunctive radiocephalic arteriovenous fistula
was done. The mean hospital stay was 5.2  0.4 days (range, 2e11 days).
Seven patients required secondary procedures. Anticoagulation was main-
tained for 12 weeks. All 32 patients resumed unrestricted use of the upper ex-
tremity, with a median interval of 3.5 months between operation and the
return to participation in competitive athletics (range, 2e10 months). The
overall duration of management from symptoms to full athletic activity
was significantly correlated with the time interval from venographic diagno-
sis to operation (r = 0.820, P < .001) and was longer in patients with persistent
symptoms (P < .05) or rethrombosis before referral (P < .01).
Conclusions. Successful outcomes were achieved for the management of ef-
fort thrombosis in a series of 32 competitive athletes using a multidisciplinary
approach based on (1) early diagnostic venography, thrombolysis, and ter-
tiary referral; (2) paraclavicular thoracic outlet decompression with external
venolysis and frequent use of subclavian vein reconstruction; and (3) tempo-
rary postoperative anticoagulation, with or without an adjunctive arteriove-
nous fistula. Optimal outcomes for venous thoracic outlet syndrome
depend on early recognition by treating physicians and prompt referral for
comprehensive surgical management.Comparisons of side effects using air and carbon dioxide foam for
endovenous chemical ablation
N. Morrison, D.L. Neuhardt, C.R. Rogers, J. McEown, T. Morrison, E. Johnson
and S.X. Salles-CunhaObjective. This clinical study evaluated prospectively adverse events imme-
diately following ultrasound-guided foam sclerotherapy (UGFS) for the treat-
ment of lower extremity venous valvular insufficiency. Incidence of side
effects associated with carbon dioxide (CO2) foam was compared with a his-
torical control using air-based foam. The literature on the subject was
reviewed.
Methods. Vital signs were monitored during and immediately after UGFS,
and adverse events were recorded for 24 hours following the procedure.
The air-based foam group had 49 patients: 44 women and 5 men. The CO2-
based foam group had 128 patients: 115 women and 13 men. CEAP class
was C2EpAsPr, describing varicose veins, primary etiology, and saphenous
reflux. UGFS followed thermal ablation of the great saphenous vein. Foam
was prepared using the three-way tap technique to mix gas with 1% polido-
canol in a 4:1 ratio. Segments of the great and small saphenous veins and
their tributaries were treated with UGFS. Foam volumes injected were 27 
10 (SD) (6e46 range) and 25  12 (6e57 range) mL for air- and CO2-based
foams respectively (P = .39). Incidence of adverse events was compared by
c2 statistics. Vital signs were compared by paired t test.
Results. During the procedure, the average heart rate decreased by less than 5
bpm for both groups (P < .001), and blood pressure decreased by less than 3
mm Hg in the CO2 group (P < .02). Respiratory rate, electrocardiogram, and
pulse oxymetry did not change significantly in both air- and CO2-foam series
(P > .05). Visual disturbances were experienced by 3.1% (4/128) and 8.2% (4/
49) patients in the CO2 and air groups respectively (P = .15). Respiratory dif-
ficulties or circumoral paresthesia each occurred in 0.8% (n = 1) of the CO2
patients. Incidence of chest tightness (3.1% vs 18%), dry cough (1.6% vs
16%), or dizziness (3.1% vs 12%) were significantly lower in the CO2 vs air
groups (P < .02). Nausea occurred in 2% and 4% of the CO2 and air-based
foam groups (P = .53). Overall, the proportion of patients describing side ef-
fects decreased from 39% (19/49) to 11% (14/128) as CO2 replaced air for
foam preparation (P < .001). Similar findings were described in the literature
of air-based foam but data on the use of physiological gas were rare.
Conclusions. Side effects decreased significantly if CO2 rather than air was
employed to make the sclerosing foam for chemical ablation of superficial
veins of the lower extremity.Eur J Vasc Endovasc Surg Vol 35, April 2008
